GenBio AI Builds First World Model of the Human Cell
18.8.2026 15:00:00 CEST | Business Wire | Press release
First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level
GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level.
A Key First in Biological and Medical Sciences:
Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by various research labs, AIDO Cell is the first to integrate the entire molecular-to-cellular spectrum into one continuous simulation. Using the system, a researcher can perturb the cell at any level and observe how the entire cell responds. Knock out a gene, for example, and watch the effects cascade from gene regulation, to changes in protein behavior, to effects on the cell as a whole.
“What's exciting here isn't that we've solved cellular biology — we haven't, at least not yet. It's that, for the first time, we have a system capable of simulating a cell across the full hierarchy of biological scales, from DNA to whole-cell behavior, in one place, which lets you interrogate it computationally,” said Baker, who received the 2024 Nobel Prize in Chemistry for his pioneering work in computational protein design. “AIDO Cell is a meaningful foundation to build on, even at this early stage, and could have major implications for fields like drug discovery, toxicology, and disease research broadly.”
AIDO Cell's multi-scale capability is made possible by an underlying world model-based architecture, representing one of the first biological applications for an emerging area of AI research. “What world model architecture enables, and what makes our system genuinely new, is that it's both multi-scale and stateful. The simulation remembers what you've done to the cell. You can run entire sequences of perturbations, where each one builds on the last, and see the evolving, cumulative effect in the cell, just as you would in a real (wet lab) workflow,” said GenBio AI President and Chief Scientist Eric Xing.
The process of bringing new drugs and therapies to market is notoriously slow, risky, and expensive. For every 10,000 compounds that enter the drug development pipeline, only one, on average, reaches the clinic. This process takes over 10 years at an estimated average cost of over US$2 billion per successful drug candidate. A major reason why is the sheer complexity of human biology and the inability of existing research tools to capture more than a fraction of it. AIDO Cell is a first step toward closing that gap. In an early case study, the system successfully recapitulated the mechanism behind imatinib in leukemia cells, demonstrating its ability to trace how a drug treatment cascades through the full cellular environment.
“We’ve released this version of the system as a preview, an early but functional demonstration that multi-scale, stateful virtual cell simulation is now possible,” said Xing. “We plan on releasing more advanced versions of the system with enhanced capabilities and accuracy later this year and over the next year.”
AIDO Cell supports K562 and HepG2 cell lines with additional cell types in development. GenBio is preparing to launch an early access/academic collaborator program to scientists across academia, biotech, and pharma.
Founding Team: GenBio AI was founded by a team combining world-leading expertise in AI, computational biology, and business:
- David Baker — Co-Founder, GenBio AI; Professor of Biochemistry, HHMI Investigator and Director of the Institute for Protein Design, University of Washington; 2024 Nobel Laureate in Chemistry
- Ziv Bar-Joseph — Co-Founder and Chief Scientific Officer, GenBio AI; Professor, Carnegie Mellon University; former Head of AI, Sanofi; Overton Prize Winner 2012
- Fred Hu — Co-Founder and CEO, GenBio AI; Founder and Chairman, Primavera Capital Group; former Partner, Goldman Sachs
- Emma Lundberg — Co-Founder and Chief Strategic Advisor, GenBio AI; Associate Professor, Stanford University; Professor, KTH Royal Institute of Technology, Co-Director, Human Protein Atlas
- Le Song — Co-Founder and Chief Technology Officer, GenBio AI; Professor, MBZUAI; former CTO and Chief AI Scientist, BioMap
- Eric Xing — Co-Founder, President and Chief Scientist, GenBio AI; President and University Professor MBZUAI; Professor, Carnegie Mellon University
In addition, Eran Segal (Dean of Biological and Life Sciences Division and Professor, MBZUAI; Professor, Weizmann Institute of Science; Overton Prize Winner 2007), and Debora Marks (Professor, Harvard University and Overton Prize Winner 2016; co-founder, Seismic Therapeutic) serve as scientific fellows.
About GenBio AI: GenBio AI is an AI for Science company on a mission to make biology fully computable. The company is building an AI-Driven Digital Organism (AIDO) to simulate living systems, decode biology holistically, and accelerate medical and scientific research, thereby transforming medicine and healthcare to benefit humanity. AIDO Cell — a world model that simulates a cell's biology from molecules to whole-cell behavior — is the first step toward that larger mission. Founded in 2024, GenBio AI is a global venture headquartered in Palo Alto, California, with labs in Paris and Abu Dhabi.
For more information, visit: genbio.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260818090648/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release
Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release
Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom